About Breast Cancer>Treatments>Targeted therapy > Targeted therapy for triple-negative breast cancer

Targeted therapy for triple-negative breast cancer


Targeted therapies, a type of systemic cancer treatment, work by targeting features called biomarkers that are needed for cancer cells to survive and grow. Until recently, chemotherapy was the only systemic treatment option for triple-negative breast cancer, and it continues to be the most effective treatment for many people. But new treatments have become available that target biomarkers found in some triple-negative breast cancers.

In this section, you’ll learn more about the different classes of targeted therapies for triple-negative breast cancer, the biomarkers that tell us who may benefit from them, and how they work.

Antibody Drug Conjugates

An antibody drug conjugate, or ADC, pairs a powerful chemotherapy medicine with a targeted therapy. The targeted therapy directs the medicine to the cancer cells, so the chemotherapy medicine can be delivered right inside them. This helps limit the side effects of the chemotherapy on healthy cells.

Several ADCs are under study for different types of breast cancer. There are two FDA approved antibody drug conjugates available for triple-negative metastatic breast cancer:


Reviewed and updated: January 4, 2021

Reviewed by: Zanetta Lamar MD


Was this page helpful?

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.